Results 131 to 140 of about 1,991,569 (312)

Safety And Efficacy Results From A Phase 1 Clinical Trial Of Ptp-001, An Injectable Placental Tissue Biologic For Knee Osteoarthritis [PDF]

, 2023
A. Amendola, S.M. Patel, D. Sullivan, V. Strand, M.K. Kottke, A. Pavesio, C.R. Flannery   +6 more
openalex   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Reporting clinical trials [PDF]

Rheumatology, 1983
J S, Dixon, A, Smith, S J, Evans
openaire   +2 more sources

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Leveraging Clinical Trial Populations and Data from the Children's Oncology Group for Cancer Survivorship Research

, 2022
Eric J. Chow, Lena E. Winestone, Philip J. Lupo, Lisa Diller, Tara O. Henderson, Nina S. Kadan‐Lottick, Jennifer Levine, Kirsten K. Ness, Smita Bhatia, Saro H. Armenian   +9 more
openalex   +2 more sources

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Strategies, Time, and Costs Associated With the Recruitment and Enrollment of Nursing Home Residents for a Micronutrient Supplementation Clinical Trial [PDF]

, 2005
P. M. Gismondi, Davidson H. Hamer, L. S. Leka, Gerard E. Dallal, M. A. Fiatarone Singh, Simin Nikbin Meydani   +5 more
openalex   +1 more source

Visualizing External Validity: Graphical Displays to Inform the Extension of Treatment Effects from Trials to Clinical Practice

, 2023
Jennifer L. Lund, Michael Webster‐Clark, Daniel Westreich, Hanna K. Sanoff, Nicholas Robert, Jennifer R. Frytak, Marley Boyd, Shahar Shmuel, Til Stürmer‎, Alexander P. Keil   +9 more
openalex   +1 more source

Clinical trials: Management of investigational products during the COVID-19 pandemic [PDF]

, 2020
Laurent Flet, Martine Tching-Sin, Adeline Chanat, Pauline Gendre, Annick Tibi   +4 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source